LXRX
- Lexicon Pharmaceuticals, Inc.
()
Overview
Company Summary
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human diseases. Operating in the healthcare sector, Lexicon specializes in the development of small molecule drugs to target and inhibit specific disease-causing genes and proteins.
The company employs a unique approach called functional genomics, which involves identifying genes and proteins involved in disease pathways. By understanding how these genes and proteins function, Lexicon is able to design and develop targeted therapies to modulate their activity and treat diseases more effectively.
Lexicon has expertise in several therapeutic areas, including diabetes, oncology, and immunology. The company has a pipeline of novel drug candidates at various stages of development, from preclinical research to late-stage clinical trials.
One of Lexicon's notable achievements is the development and commercialization of Xermelo (telotristat ethyl), an oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in adults.
Overall, Lexicon Pharmaceuticals, Inc. is dedicated to leveraging the power of genomics and innovative drug discovery approaches to bring forward new and effective therapies to improve patients' lives and address unmet medical needs.